STERIS CEO receives share and option awards

STERIS plc President and CEO Daniel A. Carestio reported equity compensation and related tax withholding transactions.

Rhea-AI Filing Summary

STERIS plc President and CEO Daniel A. Carestio reported equity compensation and related tax withholding transactions. He received 23,736 ordinary shares as a grant and 82,740 employee stock options with an exercise price of $230.74 per share, expiring in 2036.

On the same date, 2,369 restricted shares vested, and 995 of those shares were withheld at $209.76 per share to cover employment and tax obligations, rather than sold in the market. After these transactions, he directly owned 72,583 ordinary shares, of which 50,113 were restricted as of June 2, 2026, subject to a multi-year vesting schedule.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Carestio Daniel A

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	82,740	$0.00	$0.00
Grant/Award	Ordinary Shares	23,736	$0.00	$0.00
Exercise Price or Tax Liability	Ordinary Shares	995	$209.76	$209K

Holdings After Transaction: Employee Stock Option (right to buy) — 82,740 contracts (Direct); Ordinary Shares — 72,583 shares (Direct)

Footnotes (3)

1. F1. As of June 2, 2026, 50,113 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 5,937 on June 3, 2026; 4,283 on June 4, 2026; 7,912 on June 2, 2027; 5,937 on June 3, 2027; 4,283 on June 4, 2027; 7,912 on June 2, 2028; 5,937 on June 5, 2028 and 7,912 on June 4, 2029.
2. F2. 995 shares were withheld from the 2,369 restricted shares that vested on June 2, 2026. These 995 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These vested shares were valued at the NYSE closing market price on June 2, 2026.
3. F3. This option becomes exercisable as follows: 20,685 on June 2, 2027, 20,685 on June 2, 2028, 20,685 on June 4, 2029 and 20,685 on June 3, 2030.

Key Figures

Shares granted: 23,736 ordinary shares Options granted: 82,740 options at $230.74/share Tax-withheld shares: 995 shares at $209.76/share +3 more

6 metrics

Shares granted 23,736 ordinary shares Grant to CEO on June 2, 2026

Options granted 82,740 options at $230.74/share Employee stock options expiring June 2, 2036

Tax-withheld shares 995 shares at $209.76/share Shares withheld from vested restricted stock for taxes

Post-transaction holdings 73,578 ordinary shares CEO direct ownership after transactions

Restricted shares outstanding 50,113 ordinary shares Restricted as of June 2, 2026 with staged lapse

Vested restricted shares 2,369 ordinary shares Restricted shares that vested on June 2, 2026

Key Terms

restricted, Employee Stock Option (right to buy), taxes required to be withheld, NYSE closing market price

4 terms

restricted financial

"As of June 2, 2026, 50,113 of these ordinary shares are restricted."

Employee Stock Option (right to buy) financial

"Employee Stock Option (right to buy) with underlying 82,740 ordinary shares."

taxes required to be withheld financial

"These 995 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws."

NYSE closing market price financial

"These vested shares were valued at the NYSE closing market price on June 2, 2026."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did STERIS (STE) CEO Daniel Carestio receive?

Daniel Carestio received a grant of 23,736 STERIS ordinary shares and 82,740 employee stock options at an exercise price of $230.74 per share. These awards represent equity-based compensation that vests over multiple future dates according to the company’s disclosed schedule.

Were any STERIS (STE) shares sold by the CEO in this Form 4?

No open-market sale occurred; 995 shares were withheld from 2,369 vested restricted shares to satisfy tax obligations. These shares were valued at the NYSE closing market price on June 2, 2026, and reflect tax withholding rather than a discretionary sale.

How many STERIS (STE) shares does the CEO hold after these transactions?

After these transactions, Daniel Carestio directly held 73,578 STERIS ordinary shares. Of this total, 50,113 shares were restricted as of June 2, 2026, and are scheduled to lapse in tranches between 2026 and 2029 under the company’s vesting timetable.

What are the key terms of the new STERIS (STE) stock options granted to the CEO?

The CEO received 82,740 employee stock options with an exercise price of $230.74 per share and an expiration date of June 2, 2036. These options become exercisable in four equal installments between 2027 and 2030, according to the vesting schedule disclosed.

How many STERIS (STE) restricted shares vested for the CEO on June 2, 2026?

On June 2, 2026, 2,369 restricted STERIS ordinary shares vested for Daniel Carestio. From this vesting, 995 shares were withheld to cover required taxes, while the remaining vested shares increased his directly held ordinary share position at that time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/04/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carestio Daniel A

(Last) (First) (Middle)

70 SIR JOHN ROGERSON'S QUAY

(Street)

DUBLIN 2 D02 R296

(City) (State) (Zip)

IRELAND

(Country)

2. Issuer Name and Ticker or Trading Symbol
STERIS plc [ STE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/02/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/02/2026		A		23,736	A	$0	73,578(1)	D
Ordinary Shares	06/02/2026		F		995(2)	D	$209.76	72,583(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$230.74	06/02/2026		A		82,740		(3)	06/02/2036	Ordinary Shares	82,740	$0	82,740	D

Explanation of Responses:

1. As of June 2, 2026, 50,113 of these ordinary shares are restricted. The restrictions on these ordinary shares lapse as follows: 5,937 on June 3, 2026; 4,283 on June 4, 2026; 7,912 on June 2, 2027; 5,937 on June 3, 2027; 4,283 on June 4, 2027; 7,912 on June 2, 2028; 5,937 on June 5, 2028 and 7,912 on June 4, 2029.

2. 995 shares were withheld from the 2,369 restricted shares that vested on June 2, 2026. These 995 shares represent the value of the taxes required to be withheld pursuant to applicable employment or tax laws, as determined by the Issuer. These vested shares were valued at the NYSE closing market price on June 2, 2026.

3. This option becomes exercisable as follows: 20,685 on June 2, 2027, 20,685 on June 2, 2028, 20,685 on June 4, 2029 and 20,685 on June 3, 2030.

Remarks:

	/s/ John P. Ubbing, Authorized Representative under Power of Attorney	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)